Kreatech Diagnostics, an Amsterdam, Netherlands-based biotechnology company focused on the development and commercialization of molecular diagnostics, has finalised a €2m financing round.
Investors in the round include venture capital firms LSP, Alafi Capital.
The funds will be used to further expand the business. Kreatech Diagnostics develops and commercializes DNA probes and nucleic acid labeling technologies that are utilized for diagnostics and research applications in the life sciences and healthcare industry, specifically cytogenetics, molecular pathology, and microarrays.
In addition, the company appointed Kees Moonen, MA, MBA as Chief Executive Officer and Daan Ellens Ph.D. as Chairman of the Supervisory Board.